TerraBioGen Recieves Additional NRC-IRAP Funding
21 Juni 2011 - 4:00PM
Marketwired
TerraBioGen Technologies Inc. (TSX VENTURE: TBG), a developer and
marketer of proprietary technologies for the production of
organic-based, high-value agricultural products from organic
wastes, is pleased to announce that it has received approval for
additional funding from the National Research Council of Canada
Industrial Research Assistance Program (NRC-IRAP).
With the progress that the Company has made to date, NRC-IRAP is
providing further financial support for TerraBioGen's research and
development efforts with a grant of up to $36,400. This brings the
total potential NRC-IRAP funding for the identification and
characterization of bioactive compounds in the Company's products
to $175,235.
Blair Heffelfinger, President and CEO of the Company, stated,
"NRC-IRAP has been very supportive of our ongoing research and
development efforts and product innovation. This additional funding
will assist us in the isolation and characterization of additional
bioactive ingredients in our products that impart plant growth
promotion and increased crop yields benefits."
About TerraBioGen
Located in North Vancouver, BC, TerraBioGen Technologies Inc. is
committed to research and development to continue to improve the
efficiency of its technology and the quality of its agricultural
products. It is further committed to developing a worldwide
marketing capability to ensure market acceptance of its
products.
This news release contains certain statements that may be deemed
"forward-looking" statements. Forward looking statements are
statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and
similar expressions, or that events or conditions "will", "would",
"may", "could" or "should" occur. Although TerraBioGen believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from
those in forward looking statements. Forward looking statements are
based on the beliefs, estimates and opinions of TerraBioGen's
management on the date the statements are made. Except as required
by law, TerraBioGen undertakes no obligation to update these
forward-looking statements in the event that management's beliefs,
estimates or opinions, or other factors, should change.
THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT
FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES
DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED
STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT
THEREFROM.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Contacts: TerraBioGen Blair Heffelfinger President & CEO
(604) 924-1023 ext 316 (604) 924-1043 (FAX)
bheffelfinger@terrabiogen.com TerraBioGen Bob Nowell CFO &
Corporate Secretary (604) 924-1023 ext 306 (604) 924-1043 (FAX)
bnowell@terrabiogen.com
Terrabiogen Technologies (TSXV:TBG)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Terrabiogen Technologies (TSXV:TBG)
Historical Stock Chart
Von Jun 2023 bis Jun 2024